HRP20160600T1 - Peptidi koji se vežu na fgf2 i njihova upotreba - Google Patents

Peptidi koji se vežu na fgf2 i njihova upotreba Download PDF

Info

Publication number
HRP20160600T1
HRP20160600T1 HRP20160600TT HRP20160600T HRP20160600T1 HR P20160600 T1 HRP20160600 T1 HR P20160600T1 HR P20160600T T HRP20160600T T HR P20160600TT HR P20160600 T HRP20160600 T HR P20160600T HR P20160600 T1 HRP20160600 T1 HR P20160600T1
Authority
HR
Croatia
Prior art keywords
seq
peptide according
amino acid
acid sequence
tumor
Prior art date
Application number
HRP20160600TT
Other languages
English (en)
Croatian (hr)
Inventor
Marco Presta
Maura Camozzi
Marco Rusnati
Maurizio Colombo
Domenico Mastroianni
Original Assignee
Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. filed Critical Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Publication of HRP20160600T1 publication Critical patent/HRP20160600T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
HRP20160600TT 2006-01-24 2007-01-23 Peptidi koji se vežu na fgf2 i njihova upotreba HRP20160600T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06001457 2006-01-24
EP07702949.4A EP1973944B1 (en) 2006-01-24 2007-01-23 Fgf2-binding peptides and uses thereof
PCT/EP2007/000538 WO2007085412A1 (en) 2006-01-24 2007-01-23 Fgf2-binding peptides and uses thereof

Publications (1)

Publication Number Publication Date
HRP20160600T1 true HRP20160600T1 (hr) 2016-07-01

Family

ID=37421191

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20160600TT HRP20160600T1 (hr) 2006-01-24 2007-01-23 Peptidi koji se vežu na fgf2 i njihova upotreba

Country Status (19)

Country Link
US (1) US8076300B2 (enExample)
EP (1) EP1973944B1 (enExample)
JP (1) JP5427415B2 (enExample)
KR (1) KR101467453B1 (enExample)
CN (1) CN101384622B (enExample)
AU (1) AU2007209581B2 (enExample)
BR (1) BRPI0707239A8 (enExample)
CA (1) CA2637295C (enExample)
DK (1) DK1973944T3 (enExample)
EA (1) EA015339B1 (enExample)
ES (1) ES2575517T3 (enExample)
HR (1) HRP20160600T1 (enExample)
HU (1) HUE029212T2 (enExample)
IL (1) IL192800A (enExample)
MX (1) MX2008009289A (enExample)
PL (1) PL1973944T3 (enExample)
PT (1) PT1973944T (enExample)
SI (1) SI1973944T1 (enExample)
WO (1) WO2007085412A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018204928A1 (en) * 2017-05-05 2018-11-08 Board Of Regents, The University Of Texas System Fgl2 monoclonal antibodies and their use in treating malignant tumors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1298487B1 (it) * 1997-12-19 2000-01-10 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,
IT1317930B1 (it) * 2000-11-08 2003-07-15 Sigma Tau Ind Farmaceuti Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patalogie associate ad una alterata attivazione
ITRM20020109A1 (it) * 2002-02-28 2003-08-28 Sigma Tau Ind Farmaceuti Derivati funzionali della pentraxina lunga ptx3 per preparare un vaccino autologo per la cura dei tumori.

Also Published As

Publication number Publication date
MX2008009289A (es) 2008-10-17
KR101467453B1 (ko) 2014-12-01
CA2637295A1 (en) 2007-08-02
AU2007209581B2 (en) 2013-03-28
CN101384622B (zh) 2013-03-27
DK1973944T3 (en) 2016-06-27
SI1973944T1 (sl) 2016-07-29
BRPI0707239A8 (pt) 2018-01-30
ES2575517T3 (es) 2016-06-29
KR20080096794A (ko) 2008-11-03
IL192800A0 (en) 2009-02-11
WO2007085412B1 (en) 2007-10-11
JP2009523457A (ja) 2009-06-25
IL192800A (en) 2015-04-30
EA015339B1 (ru) 2011-06-30
BRPI0707239A2 (pt) 2011-04-26
HUE029212T2 (en) 2017-02-28
CN101384622A (zh) 2009-03-11
EP1973944A1 (en) 2008-10-01
PL1973944T3 (pl) 2016-09-30
PT1973944T (pt) 2016-07-07
EA200870188A1 (ru) 2009-02-27
US20090215689A1 (en) 2009-08-27
EP1973944B1 (en) 2016-05-11
WO2007085412A1 (en) 2007-08-02
CA2637295C (en) 2017-06-13
AU2007209581A1 (en) 2007-08-02
US8076300B2 (en) 2011-12-13
JP5427415B2 (ja) 2014-02-26

Similar Documents

Publication Publication Date Title
CA2120303C (en) Cyclic adhesion inhibitors
TW517064B (en) Cyclic adhesion inhibitors
JP2010505444A5 (enExample)
KR100905380B1 (ko) 신경펩타이드-2 수용체(ｙ２ｒ) 작용물질 활성을 갖는펩타이드
HRP20140616T1 (hr) Peptidni analog oksintomodulina
US8748575B2 (en) Therapeutic peptides
JP2008501310A6 (ja) 胃腸障害の治療のための方法および組成物
CN101010335A (zh) 治疗胃肠病的方法和组合物
WO2005091944A2 (en) Glycol linked fgf-21 compounds
JP2013518115A5 (enExample)
AU697614B2 (en) Novel cyclopeptides for the preparation of medicaments
JP2005516885A5 (enExample)
JP2016518351A5 (enExample)
US11414474B2 (en) Long-acting adrenomedullin derivatives
JP2011518179A5 (enExample)
CN101143894A (zh) 高效抑制血管生成多肽及其物理化学修饰方法和应用
RU2007110981A (ru) Урокортин iii и его использование
JP2012508698A5 (enExample)
JP2003500456A (ja) 角質細胞増殖因子−２製剤
JP2014513941A5 (enExample)
JP2009535330A5 (enExample)
JP2000510102A (ja) 環状接着阻害剤
JP2009502803A5 (enExample)
US9611297B1 (en) Compositions and methods for the treatment of cast nephropathy and related conditions
JP2008526935A5 (enExample)